TY  - EJOU
AU  - LI, Wen 
AU  - YANG, Junli 
AU  - ZHOU, Dong 
AU  - ZHANG, Jinghui 
AU  - ZHUO, Qingcui 

TI  - Meta-analysis evaluation of the treatment of neonatal hypoxic– ischemic encephalopathy with ganglioside
T2  - BIOCELL

PY  - 2019
VL  - 43
IS  - 1
SN  - 1667-5746

AB  - The efficacy and safety of ganglioside in the treatment of neonates who suffer from hypoxic–ischemic
encephalopathy (HIE) needs to be fully evaluated. We searched the following databases: PubMed, ScienceDirect,
LISTA, CNKI, Chinese biomedical literature database and Wanfang digital journals of full-text database to determine
the inclusion and exclusion criteria of papers and a total of 12 papers were included after quality evaluation. Then we
conducted the meta-analysis with RevMan5.0 software. The results showed that compared with the control group, the
abnormal rate declined in the ganglioside-treated group (relative risk (RR)=0.27, 95% confidence interval (CI)= 0.05–
1.96). NBNA records of the 7, 10–14d neonates were improved effectively: RR (95% CI) were 2.28 (0.86–3.42) and 2.53
(1.04–2.92) respectively. Neural system sequelae incidence was reduced significantly: RR (95% CI) = 0.35: (0.15–0.79).
Ganglioside treatment could effectively reduce the abnormality rate of head size, improve the neurological score, reduce
the incidence of neurological sequelae, and significantly prompt clinical recovery for neonates with HIE.
KW  - Ganglioside
KW  -  Hypoxic–ischemic encephalopathy
KW  -  Meta-analysis
KW  -  Neonate

DO  - 10.32604/biocell.2019.04763